Skip to main content
Premium Trial:

Request an Annual Quote

Danaher: Jose-Carlos Gutierrez-Ramos

Danaher has named Jose-Carlos Gutierrez-Ramos as its chief scientific officer and senior VP. He will be an executive officer of the company tasked with defining Danaher's science and technology strategy. He joins Danaher from Abbvie, where he served as head of global drug discovery. Gutierrez-Ramos also previously served as president and CEO of Repertoire Immune Medicines and Synlogic, and prior to that held R&D positions at Pfizer, GlaxoSmithKline, Avidia, and Millennium Pharmaceuticals. He also was a professor at Harvard Medical School in the Department of Genetics and a professor for the Spanish Scientific Research Council.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.